CARsgen Therapeutics (2171.HK) Q4 2025 Earnings Report

CARsgen Therapeutics reported QQ4 2025 results that underscore a transition from early-stage revenue to a more meaningful top-line contribution, driven by ongoing pipeline activity and improved quarterly execution. Revenue for QQ4 2025 was 73.45 million CNY, up QoQ by 34.19%, with gross margin of 67.71% and a gross profit of 49.74 million CNY. The quarter featured a substantial R&D spend of 113.22 million CNY, contributing to an operating loss of 92.84 million CNY and an EBITDA of -76.32 million CNY. Net income came in at -22.15 million CNY, or -30.15% net margin, reflecting the company’s continued emphasis on advancing its CART and antibody programs rather than achieving near-term profitability.

Cash and cash equivalents stood at 1.12 billion CNY at period end, with total debt of 61.20 million CNY and net debt of -1.06 billion CNY, yielding a strong liquidity position and ample runway to fund key clinical milestones. The balance sheet remains solid, supported by current assets of 1.18 billion CNY and a healthy current ratio (~5.7x) versus short-term liabilities. Cash flow from operations was negative (-47.45 million CNY) as the company continued to invest in its development roadmap, while financing activities and FX movements influenced the net change in cash. Management emphasized a pipeline-centric strategy, with CT053 (autologous CART) in pivotal Phase II in China for relapsed/refractory multiple myeloma, CT041 (gastric/gastroesophageal) in early to mid-stage trials in China and the US, and CT011/CT032/CT017 across hepatocellular carcinoma and B-cell lymphoma programs, indicating multiple near- to mid-term catalysts.

Overall, the QQ4 2025 results reflect a biotech in growth mode: robust upfront gross margins on a small revenue base, steep but purposeful R&D investment aimed at material pipeline milestones, and a substantial liquidity cushion that supports ongoing trial activity. The key question for investors is whether the company can translate its clinical progress and eventual readouts into meaningful equity value as trials mature and potential partnerships materialize.